melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
In September 2015, chairman Russ Withers and chief executive Warren Wilmot announced they were resigning from the company. Deputy chairman Michael Smith replaced Withers, while Bob Baily was appointed as interim chief executive. In December 2015, Stewart Levitt of law firm Levitt Robinson Solicitors, who featured prominently in the Four Corners program, announced a potential class action lawsuit against 7-Eleven head office on behalf of franchisees who had allegedly been lured into signing on with 7-Eleven by false representations. This announcement was made on the same day as a Court finding describing Levvit Robinson's "hellish bullying" of Dr Brendan French, miring the action in controversy. Also on that day, 7-Eleven offered to pay "the first $25 million of back-pay claims brought by current and former workers. Franchisees would then pay the next $5 million and any payments after that would be split 50-50 between head office and franchisees." Fels "described the $25 million offer from head office as a 'significant step forward'" but added that his panel's investigation would not be effected. 7-Eleven ultimately paid more than $173 million for "systematic wage theft" to workers employed between 2015 and 2020. Levvit Robinson was forced to retract misleading statements made in advertising to 7-Eleven franchisees in June 2018 by the Federal Court of Australia. This occurred only months after Levvit Robinson launched a new class action against 7-Eleven that included the ANZ Bank despite banks having stopped loans to 7-Eleven franchisees in 2015.
Phenylacetic acid was added to switch it to producing the highly potent penicillin G. This strain could produce up to 550 milligrams of penicillin per litre. Pfizer was a small New York company that specialised in making citric acid, for which it had developed deep submergence techniques. This involved converting molasses to citric acid by fermenting it in a large tank in which it was stirred and the pH was carefully controlled. Pfizer's vice president, John L. Smith, whose daughter had died from an infection, put all of Pfizer's resources into the development of a practical deep submergence technique. The company invested $2.98 million in penicillin in 1943 and 1944 (equivalent to $55 million in 2025). Pfizer scientists Jasper H. Kane, G. M. Shull, E. M. Weber, A. C. Finlay and E. J. Ratajak worked on the fermentation process while R. Pasternak, W. J. Smith, V. Bogert and P. Regna developed extraction techniques.
== Notable people with sleep apnea == Joe Biden – Former President of the United States, who uses a CPAP machine to manage a history of obstructive sleep apnea dating back to 2008. Jack Black – American actor and musician, who publicly discussed navigating his diagnosis and his reliance on a CPAP machine. Brett Favre – Hall of Fame NFL quarterback, who noted that his diagnosis of obstructive sleep apnea and subsequent daytime fatigue contributed to his decision to retire from professional football. Carrie Fisher – American actress and author, whose official coroner's report cited sleep apnea as a primary contributing factor in her 2016 death. Shaquille O'Neal – Hall of Fame NBA basketball player, who partnered with Harvard Medical School to produce public health materials after being diagnosed with severe obstructive sleep apnea. Amy Poehler – Emmy-winning actress and writer, who openly detailed her severe, exhausting experiences with the sleep condition in her autobiography. Tyler Reddick – American racing driver, who partnered with a CPAP company after being diagnosed with OSA. Reggie White – NFL defensive lineman, whose death at age 43 from cardiac arrhythmia was heavily attributed to complications from untreated sleep apnea, prompting his widow to found a national sleep education foundation that also provides affordable CPAP equipment to those who might otherwise be unable to pay for it.
Sources: en.wikipedia.org
==== Operation Arctic Sentry ==== On 11 February, NATO launched Operation Arctic Sentry, a military exercise led by JFC Norfolk aimed to strengthen NATO's posture in the Arctic, with Supreme Allied Commander Europe Alexus Grynkewich stating that it "underscores the alliance's commitment to safeguard its members and maintain stability." While the operation is not intended to be permanent, Canadian Foreign Affairs minister Anita Anand urges it to be otherwise, commenting that "defending the Arctic is defending NATO's northern flank and North America itself". Despite being officially intended to counter Sino–Russian threats in the Arctic, Operation Arctic Sentry has often been interpreted that it's largely meant to "appease Trump" regarding Greenland instead. According to Deutsche Welle, participating countries would include the United States, Canada, Denmark, Norway, Sweden, Finland, and Iceland.
==== Activation ==== Macrophages can achieve different activation phenotypes through interactions with different subsets of T helper cells, such as TH1 and TH2. Although there is a broad spectrum of macrophage activation phenotypes, there are two major phenotypes that are commonly acknowledged. They are the classically activated macrophages, or M1 macrophages, and the alternatively activated macrophages, or M2 macrophages. M1 macrophages are proinflammatory, while M2 macrophages are mostly anti-inflammatory.
Scarborough (; 2021 Census 623,610) is a district of Toronto, Ontario, Canada, situated in the eastern part of Toronto. Its borders are Victoria Park Avenue to the west, Steeles Avenue and the city of Markham to the north, Rouge River and the city of Pickering to the east, and Lake Ontario to the south. Scarborough was named after the English town of Scarborough, North Yorkshire, inspired by its cliffs. Scarborough is the site of several former Indigenous settlements dating back many centuries. It was settled by Europeans in the 1790s and has grown from a collection of small rural villages and farms to become a fully urbanized and diverse cultural community. Incorporated in 1850 as a township, the district became part of Metropolitan Toronto in 1953 and was reconstituted as a borough in 1967. The borough rapidly developed as a suburb of Toronto over the next decade and became a city in 1983. In 1998, the city and the rest of Metropolitan Toronto were amalgamated into the present city of Toronto. The Scarborough Civic Centre – the former city's last seat of government – now houses offices of the municipal government of Toronto. Since the end of the Second World War, the district has been a popular destination for new immigrants in Canada. As a result, it is one of the most diverse and multicultural areas in the Greater Toronto Area, being home to various religious groups and places of worship. It includes a number of natural landmarks, including the Toronto Zoo, Rouge Park, and the Scarborough Bluffs.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.